Spike Ferritin Nanoparticle Covid-19 vaccine
The US Army has recently developed a SARS-CoV-2 sub-unit vaccine based on a ferritin nanoparticle platform that displays a pre-fusion
Tag: Covid-19
Alpha-cyclodextrin and Hydroxytyrosol against SARS-CoV-2 infection
In the last year, the Cyclodextrin News reported on an oral spray containing alpha-cyclodextrin and hydroxytyrosol developed by Italian researchers
HPBCD solubilized pazopanib against lung injuries due to coronavirus infection
Professor Wu Dianquing at Yale university has discovered that a widely used anticancer drug, pazopanib might be suitable for treating
Molecular interactions in remdesivir-cyclodextrin systems
In a recently published study intermolecular interactions of remdesivir and various cyclodextrin derivatives were characterized by extensive NMR spectroscopy. The
Remdesivir interactions with sulfobutylether-b-cyclodextrins: A case study using selected substitution patterns
A structural and thermodynamic analysis for the interaction between SBECD and neutral or protonated remdesivir has been performed using multiple
Cyclodextrin Market size would exceed USD 390 million valuation by 2027, Says to Global Market Insights Inc.
The growth of the cyclodextrin market is driven by burgeoning demand for remdesivir injections due to COVID-19, expanding cosmetics &
Role of HPBCD in development of Pfizer’s novel COVID-19 oral antiviral treatment candidate
Pfizer’s breakthrough drug candidate PF-07321332 used in combination with ritonavir was poven to successfully reduce the risk of hospitalization and
METHYL-CYCLODEXTRIN FOR USE IN TREATING ENVELOPED VIRUS INFECTIONS SUCH AS SARS-CoV-2
The patent application (1) with priority date of 09. March 2020 claims that methyl bCD preferably with DS 0.7 (Crysmeb)
Memorial Sloan Kettering Cancer Center: Potential treatment of COVID-19 using inhalable camostat/nafamostat formulated with HPBCD or SBECD
Memorial Sloan Kettering Cancer Center (MSKCC) has filed a patent application on an inhalational therapeutic composition of camostat solubilized by
Updates on development of oral remdesivir formulations
Jubilant Pharmova subsidiary Jubilant Pharma has concluded safety and pharmacokinetic/absorption studies of a new oral formulation of remdesivir in animals